Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects
Teratology · 1988-08 · 38 (2) · 135-144
DOI: 10.1002/tera.1420380206 ↗Abstract
Abstract Medroxyprogesterone acetate (MPA; Provera) was given orally to 449 women from the 5th to 7th week of pregnancy until at least the 18th week. Data are recorded from two treatment groups (recurrent abortion and threatened abortion) and are compared to a matched series. A total of 1,016 pregnancies are included in the study, and all patients were recruited from a subfertile population conceiving from a range of infertility treatments. Early pregnancy wastage was high throughout the groups and was significantly elevated (43%; P
EUVIMED